Camrelizumab plus chemotherapy versus concurrent chemoradiotherapy as neoadjuvant therapy for resectable thoracic oesophageal squamous cell cancer (REVO): A multicenter, randomized, open-label, phase II trial

被引：2

作者：

Yuan, W. P. ^{[1
]}

Chen, Y. ^{[1
]}

Liu, J. ^{[2
]}

Zhang, W. ^{[3
]}

Chen, X. ^{[1
]}

He, H. ^{[1
]}

Chen, P. ^{[1
]}

Lin, J-P. ^{[1
]}

Zhang, D. ^{[1
]}

Lin, H. ^{[1
]}

Wei, W. ^{[1
]}

Chen, W. ^{[1
]}

Zhou, H. ^{[1
]}

Gao, P. ^{[1
]}

Liu, S. ^{[1
]}

Wang, F. ^{[1
]}

机构：

[1] Fujian Med Univ, Dept Thorac Oncol Surg, Clin Oncol Sch, Fujian Canc Hosp, Fuzhou, Peoples R China

[2] Zhangzhou Second Hosp, Dept Thorac Surg, Zhangzhou, Peoples R China

[3] Fujian Med Univ, Dept Cardiothorac Surg, Zhangzhou Affiliated Hosp, Zhangzhou, Peoples R China

来源：

关键词：

D O I：

10.1016/j.annonc.2023.09.1435

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1522P

引用

页码：S857 / S857

页数：1